miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment. miR-524-5p is considered as a tumor suppressor in many cancers, including melanoma. In this study, we investigated the biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Mai-Huong Thi, Lin, Chen-Huan, Liu, Szu-Mam, Miyashita, Azusa, Ihn, Hironobu, Lin, Hsuan, Ng, Chi Hou, Tsai, Jen-Chieh, Chen, Ming-Hong, Tsai, Mu-Shiun, Lin, In-Yu, Liu, Shu-Chen, Li, Long-Yuan, Fukushima, Satoshi, Lu, Jean, Ma, Nianhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642759/
https://www.ncbi.nlm.nih.gov/pubmed/33142243
http://dx.doi.org/10.1016/j.neo.2020.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642759/
https://www.ncbi.nlm.nih.gov/pubmed/33142243
http://dx.doi.org/10.1016/j.neo.2020.10.009

Ejemplares similares